Because of the potential side effects of heparin, methods of regional citrate anticoagulation (RCA) for continuous renal replacement therapy (CRRT) have been gaining wider acceptance with the development of simplified and safer protocols. Advantages of RCA include the avoidance of systemic anticoagulation and heparin-induced thrombocytopenia. The disadvantage is that citrate can add complexity and labor intensity to CRRT. Frequent monitoring of electrolytes, ionized calcium, and acid-base status is required, due to the potential for hypernatremia, metabolic alkalosis, and systemic ionized hypocalcemia. If properly monitored, complications associated with RCA are uncommon. A variety of methods of delivering RCA are described in the literature. Overall, studies of RCA, as compared to unfractionated heparin, report better filter survival times and less bleeding. In this section, we summarize the characteristics of citrate as an anticoagulant and provide an update of citrate use in CRRT.

Keywords:
Continuous renal replacement therapy, Regional citrate anticoagulation, Heparin-induced thrombocytopenia
1.
Amanzadeh J, Reilly RF: Anticoagulation and continuous renal replacement therapy. Semin Dial 2006;19:311–316.
2.
Calatzis A, Toepfer M, Schramm W, Spannagl M, Schiffl H: Citrate anticoagulation for extracorporeal circuits: effects on whole blood coagulation activation and clot formation. Nephron 2001;89:233–236.
3.
Pinnick RV, Wiegmann TB, Diederich DA: Regional citrate anticoagulation for haemodialysis in the patient at high risk for bleeding. N Engl J Med 1983;308:258–261.
4.
Davenport A, Tolwani A: Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. Nephrol Dial Transplant Plus 2009;2:439–447.
5.
Meier-Kriesche HU, Gitomer J, Finkel K, Du Bose T: Increased total to ionised calcium ratio during continuous venovenous haemodialysis with regional citrate anticoagulation. Crit Care Med 2001;29:748–752.
6.
Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C, Gangl A: Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003;31:2450–2455.
7.
Saner F, Treckmann J, Geis A, Lösch C, Witzke O, Canbay A, Herget-Rosenthal S, Kribben A, Paul A, Feldkamp T: Efficacy and safety of regional citrate anticoagulation in liver transplant patients requiring post-operative renal replacement therapy. Nephrol Dial Transplant 2012;27:1651–1657.
8.
Mehta RL, McDonald BR, Aguilar MM, Ward DM: Regional citrate anticoagulation for continuous arteriovenous haemodialysis in critically ill patients. Kidney Int 1990;38:976–981.
9.
Oudemans-van Straaten HM, Fiaccadori, Baldwin I: Anticoagulation for renal replacement therapy: different methods to improve safety. Practice of renal replacement therapy in the ICU; in Ronco C, Bellomo R, McCullough PA (eds): Cardiorenal Syndromes in Critical Care. Contrib Nephrol. Basel, Karger, 2010, vol 165, pp 251–262.
10.
Morgera S, Schneider M, Slowinski T, Vargas-Hein O, Zuckermann-Becker H, Peters H, Kindgen-Milles D, Neumayer H: A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med 2009;37:2018–2024.
11.
Tolwani AJ, Prendergast MB, Speer RR, Wille KM: A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance. Clin J Am Soc Nephrol 2006;1:79–87.
12.
Zhang Z, Hongying N: Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. Intensive Care Med 2012;38:20–28.
13.
Bos JC, Grooteman MP, van Houte AJ, Schoorl M, van Limbeek J, Nube MJ: Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. Nephrol Dial Transplant 1997;12:1387–1393.
14.
Hofbauer R, Moser D, Frass M, Oberbauer R, Kaye AD, Wagner O, Kapiotis S, Druml W: Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney Int 1999;56:1578.
15.
Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P: Citrate vs heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004;30:260–265.
16.
Kutsogiannis DJ, Gibney RT, Stollery D, Gao J: Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005;67:2361–236.
17.
Betjes MG, van Oosterom D, van Agteren M, van de Wetering J: Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. J Nephrol 2007;20:602–608.
18.
Fealy N, Baldwin I, Johnstone M, Egi M, Bellomo R: A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. Int J Artif Organs 2007;30:301–307.
19.
Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF: Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009;37:545–552.
20.
Hetzel GR, Schmitz M, Wissing H, Ries W, Schott G, Heering PJ, Isgro F, Kribben A, Himmele R, Grabensee B, Rump LC: Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2011;26:232–239.
21.
Wu M, Hsu Y, Bai C, Lin Y, Wu C, Tam K: Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2012;59:810–818.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.